Intramuscular @entity2892 / XXXX for treatment of mild and moderately severe @entity2348 .

@entity1 @entity1712 @entity2892 @entity9234 @entity2348 @entity1729 @entity5280 @entity293
The efficacy and safety of intramuscularly administered @entity2892 / @entity9234 was studied in 70 @entity1 with mild or moderately severe @entity2348 (skin and soft tissue infections, @entity1729 , @entity293 and @entity5280 ). Doses of @entity2892 / @entity9234 ranged from 0.5 to 0.75 g twice daily. Fifty-five @entity1 were evaluable for bacteriological efficacy; in the remaining 15 @entity1 no pathogens were isolated or susceptibility data were lacking. MIC50 and MIC90 of @entity2892 were 0.12 mg/l and 0.5 mg/l, respectively, for Gram-negative pathogens isolated and 0.25 mg/l and 0.5 mg/l, respectively, for Gram-positive pathogens. Only one strain (a Flavobacterium odoratum) was resistant to @entity2892 . Clinical cure and bacteriological elimination was achieved in 94% of evaluable @entity1 while 3% showed marked clinical improvement. Two @entity1 were considered therapeutic failures. No clinical adverse effects were noted. Abnormal liver transaminases were recorded in 23% of the @entity1 and 11% developed @entity1712 . In no @entity1 was @entity2892 / @entity9234 discontinued due to adverse effects. It is concluded that intramuscular @entity2892 / @entity9234 in these @entity1 was well tolerated and efficacious.
